Your browser doesn't support javascript.
loading
Updated treatment of castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology ; (12): 1136-1140, 2014.
Article in Chinese | WPRIM | ID: wpr-319552
ABSTRACT
Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any therapeutic options currently used can improve the 2- to 3-year survival of the patient. Recently, some new drugs for the treatment of CRPC through various action mechanisms have been approved, and others are in the advanced stage of clinical trial. This review provides an overview of these new therapeutic agents.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Prostatic Neoplasms / General Surgery / Orchiectomy / Mortality / Therapeutic Uses / Drug Therapy / Prostatic Neoplasms, Castration-Resistant / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Prognostic study Limits: Humans / Male Language: Chinese Journal: National Journal of Andrology Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Prostatic Neoplasms / General Surgery / Orchiectomy / Mortality / Therapeutic Uses / Drug Therapy / Prostatic Neoplasms, Castration-Resistant / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Prognostic study Limits: Humans / Male Language: Chinese Journal: National Journal of Andrology Year: 2014 Type: Article